Structured evidence table for Alpha-Gpc Cognition Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Alpha-Gpc Cognition Randomized Trial | As measured by the Sandoz Clinical Assessment for Geriatric Patients (SCAG), choline alphoscerate significantly improved clinical conditions in patients with dementia disorders compared with citicoline at the end of treatment [WMD: -3.92 (95% CI: -7.41 to -0.42)]. | 1 | Sagaro GG (2025) | Comparison of the effects of choline alphoscerate and citicoline in patients with dementia disorders: a systematic review and meta-analysis. |
| Alpha-Gpc Cognition Randomized Trial | Conclusion Our findings indicate that choline alphoscerate is more effective than citicoline in improving the clinical conditions of dementia patients. | 1 | Sagaro GG (2025) | Comparison of the effects of choline alphoscerate and citicoline in patients with dementia disorders: a systematic review and meta-analysis. |
| Alpha-Gpc Cognition Randomized Trial | Background Over 44 million people worldwide live with dementia, affecting their quality of life and well-being. | 1 | Sagaro GG (2025) | Comparison of the effects of choline alphoscerate and citicoline in patients with dementia disorders: a systematic review and meta-analysis. |
| Alpha-Gpc Cognition Randomized Trial | Choline alphoscerate and citicoline supplements are commonly used to improve cognitive function in dementia patients. | 1 | Sagaro GG (2025) | Comparison of the effects of choline alphoscerate and citicoline in patients with dementia disorders: a systematic review and meta-analysis. |
| Alpha-Gpc Cognition Randomized Trial | Most basic or translational researchers have to find the medical evidence of AD research from Aβ aggregation, phosphorylation of tau, enzyme assay such as AchEI or BACE, etc, whereas the others looked for the large scale screening multi-omics approach to find a target molecule from big data, sometimes presenting pre- or clinical neuropsychological tests, or PET imagings such as amyloid or tau. | 4 | Kim Manho (2025) | Current clinical trends in developing strategies for dementia disorders and the role of Korean Red Ginseng |
| Alpha-Gpc Cognition Randomized Trial | Lecanemab, on the other hand, has shown more promising results in clinical trials, with evidence suggesting it may help preserve cognitive function while also reducing pathological brain burden []. | 4 | Kim Manho (2025) | Current clinical trends in developing strategies for dementia disorders and the role of Korean Red Ginseng |
| Alpha-Gpc Cognition Randomized Trial | In conclusion, monoclonal antibodies represent a promising step forward in Alzheimer's treatment by addressing the core pathological features of the disease. | 4 | Kim Manho (2025) | Current clinical trends in developing strategies for dementia disorders and the role of Korean Red Ginseng |
| Alpha-Gpc Cognition Randomized Trial | [1] [2] [3] [4] [1] [2] [3] 3 Only a few years ago, new treatment of Alzheimer's disease (AD) has been approved by FDA, using the development of monoclonal antibody therapy. | 4 | Kim Manho (2025) | Current clinical trends in developing strategies for dementia disorders and the role of Korean Red Ginseng |
Source documents